Document Detail

Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
MedLine Citation:
PMID:  7926977     Owner:  NLM     Status:  MEDLINE    
BACKGROUND. Tumor necrosis factor (TNF) and interleukin-1 beta (IL-1) are two cytokines with erythropoietic inhibitory activity which may be involved in the pathogenesis of some types of anemia that may respond to recombinant erythropoietin (r-EPO). The aim of the present study was to evaluate whether TNF and IL-1 serum levels are related to clinical response in patients with myelodysplastic syndromes (MDS) receiving r-EPO. TNF and IL-1 serum levels were measured by means of immunoenzymatic assays in 26 patients affected by MDS and treated with r-EPO administered subcutaneously at dosages up to 1050 U/kg a week, for at least two months. Four patients (15%) showed a significant response, with an increase of hemoglobin > 2 g/dL and complete suspension of transfusions. Higher mean serum levels of both TNF (54.2 +/- 93 vs 4.2 +/- 7.9 pg/mL, p < 0.001) and IL-1 (114 +/- 58.5 vs 36.1 +/- 21.7 pg/mL, p < 0.001) were measured in MDS patients than in a group of 42 normal controls. However, responders showed significantly lower mean levels of TNF (8.2 +/- 9.6 vs 58.5 +/- 65.2 pg/mL, p < 0.05) and IL-1 (30 +/- 24.8 vs 127.8 +/- 51.4 pg/mL, p < 0.001) than those of non responders. In terms of absolute values, all responders evidenced undetectable or normal levels of both cytokines. No relationship was found between TNF or IL-1 and values of hemoglobin, serum erythropoietin, ferritin, soluble transferrin receptor or transfusional requirements. MDS patients who respond to r-EPO have lower serum levels of TNF and IL-1 than those who do not respond.
P Musto; R Matera; M M Minervini; C Checchia-de Ambrosio; C Bodenizza; A Falcone; M Carotenuto
Related Documents :
9389937 - Interleukin-12 in early or advanced cancer patients.
9250887 - Clinical significance of erythrosedimentation rate in cancer in relation to cytokine pr...
18187137 - Cystatin c--a marker of peripheral atherosclerotic disease?
15939097 - Serum c-reactive protein elevation predicts poor clinical outcome in patients with dist...
1084157 - Immunological classification of acute lymphoblastic leukaemias: evaluation of its clini...
11456307 - Subclinical dopaminergic dysfunction in asymptomatic parkinson's disease patients' rela...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Haematologica     Volume:  79     ISSN:  0390-6078     ISO Abbreviation:  Haematologica     Publication Date:    1994 May-Jun
Date Detail:
Created Date:  1994-11-10     Completed Date:  1994-11-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  265-8     Citation Subset:  IM    
Division of Hematology, IRCCS Casa Sollievo della Sofferenza Hospital, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Erythropoietin / therapeutic use*
Interleukin-1 / blood*
Middle Aged
Myelodysplastic Syndromes / blood*,  drug therapy*
Recombinant Proteins / therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha / metabolism*
Reg. No./Substance:
0/Interleukin-1; 0/Recombinant Proteins; 0/Tumor Necrosis Factor-alpha; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multiple myeloma associated with autoimmune hemolytic anemia.
Next Document:  Flow cytometric analysis of anti-platelet antibodies in idiopathic thrombocytopenic purpura.